Market Research Logo

Diabetic Nephropathy - Pipeline Review, H2 2015

Diabetic Nephropathy - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H2 2015’, provides an overview of the Diabetic Nephropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diabetic Nephropathy Overview
Therapeutics Development
Pipeline Products for Diabetic Nephropathy - Overview
Pipeline Products for Diabetic Nephropathy - Comparative Analysis
Diabetic Nephropathy - Therapeutics under Development by Companies
Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes
Diabetic Nephropathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Diabetic Nephropathy - Products under Development by Companies
Diabetic Nephropathy - Products under Investigation by Universities/Institutes
Diabetic Nephropathy - Companies Involved in Therapeutics Development
AbbVie Inc.
Aerpio Therapeutics, Inc.
Antisense Therapeutics Limited
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
BiOrion Technologies B.V.
Cellmid Limited
ChemoCentryx, Inc.
Concert Pharmaceuticals, Inc.
CSL Limited
CTI BioPharma Corp.
Daiichi Sankyo Company, Limited
Dimerix Bioscience Pty Ltd
Dong Wha Pharma Co., Ltd.
Dynamis Therapeutics, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Galectin Therapeutics, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Glucox Biotech AB
GNI Group Ltd.
Islet Sciences, Inc.
Jazz Pharmaceuticals Plc
Jenrin Discovery, Inc.
Johnson & Johnson
Mallinckrodt Plc
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
MorphoSys AG
NephroGenex, Inc.
Noxxon Pharma AG
Omeros Corporation
OncoImmune, Inc.
Otsuka Holdings Co., Ltd.
Pfizer Inc.
PhytoHealth Corporation
ProMetic Life Sciences Inc.
Serodus ASA
Shire Plc
Takeda Pharmaceutical Company Limited
Tobira Therapeutics, Inc.
Torrent Pharmaceuticals Limited
Vascular Pharmaceuticals, Inc.
Vicore Pharma AB
XOMA Corporation
Diabetic Nephropathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
11-RVIVIT - Drug Profile
A-717 - Drug Profile
Antibodies to Inhibit Heparanase for Cancer - Drug Profile
APX-115 - Drug Profile
ASP-8232 - Drug Profile
ATL-1103 - Drug Profile
atrasentan hydrochloride - Drug Profile
baricitinib - Drug Profile
Biologic for Diabetic Nephropathy - Drug Profile
BOT-191 - Drug Profile
C-21 - Drug Profile
canagliflozin - Drug Profile
CCX-140 - Drug Profile
cenicriviroc mesylate - Drug Profile
corticotropin - Drug Profile
CS-3150 - Drug Profile
CSL-346 - Drug Profile
CTP-499 - Drug Profile
Cyndacel-M - Drug Profile
DMX-250 - Drug Profile
Drug for Diabetic Nephropathy - Drug Profile
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile
DT-23552 - Drug Profile
DW-1029M - Drug Profile
DYN-12 - Drug Profile
emapticap pegol - Drug Profile
finerenone - Drug Profile
gevokizumab - Drug Profile
GKT-136901 - Drug Profile
GKT-831 - Drug Profile
GRMD-02 - Drug Profile
GW-610742 - Drug Profile
JD-5037 - Drug Profile
JNJ-39933673 - Drug Profile
KBP-5074 - Drug Profile
lisofylline - Drug Profile
MLN-1202 - Drug Profile
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile
Monoclonal Antibody to Inhibit HPTPbeta for Diabetic Nephropathy - Drug Profile
Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders - Drug Profile
MOR-107 - Drug Profile
MPC-300IV - Drug Profile
MT-3995 - Drug Profile
Nephrilin - Drug Profile
Oligotide - Drug Profile
oxypurinol - Drug Profile
PBI-4050 - Drug Profile
PBI-4547 - Drug Profile
PF-00489791 - Drug Profile
PHN-033 - Drug Profile
pirfenidone - Drug Profile
pirfenidone - Drug Profile
probucol - Drug Profile
Pyridoxamine Dihydrochloride - Drug Profile
selonsertib - Drug Profile
SER-150 - Drug Profile
SHP-627 - Drug Profile
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile
Small Molecules for Diabetic Nephropathy - Drug Profile
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile
SP-20202 - Drug Profile
TAK-272 - Drug Profile
TAK-648 - Drug Profile
TBE-31 - Drug Profile
TD-0714 - Drug Profile
TRC-120038 - Drug Profile
VPI-2690B - Drug Profile
VS-105 - Drug Profile
XRX-108 - Drug Profile
XRX-221 - Drug Profile
Diabetic Nephropathy - Recent Pipeline Updates
Diabetic Nephropathy - Dormant Projects
Diabetic Nephropathy - Discontinued Products
Diabetic Nephropathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Nephropathy, H2 2015
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Diabetic Nephropathy - Pipeline by AbbVie Inc., H2 2015
Diabetic Nephropathy - Pipeline by Aerpio Therapeutics, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H2 2015
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H2 2015
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2015
Diabetic Nephropathy - Pipeline by Bayer AG, H2 2015
Diabetic Nephropathy - Pipeline by BiOrion Technologies B.V., H2 2015
Diabetic Nephropathy - Pipeline by Cellmid Limited, H2 2015
Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Concert Pharmaceuticals, Inc., H2 2015
Diabetic Nephropathy - Pipeline by CSL Limited, H2 2015
Diabetic Nephropathy - Pipeline by CTI BioPharma Corp., H2 2015
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015
Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H2 2015
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H2 2015
Diabetic Nephropathy - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H2 2015
Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H2 2015
Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H2 2015
Diabetic Nephropathy - Pipeline by GlaxoSmithKline Plc, H2 2015
Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H2 2015
Diabetic Nephropathy - Pipeline by GNI Group Ltd., H2 2015
Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Jazz Pharmaceuticals Plc, H2 2015
Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2015
Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H2 2015
Diabetic Nephropathy - Pipeline by Mesoblast Limited, H2 2015
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2015
Diabetic Nephropathy - Pipeline by NephroGenex, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2015
Diabetic Nephropathy - Pipeline by Omeros Corporation, H2 2015
Diabetic Nephropathy - Pipeline by OncoImmune, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Diabetic Nephropathy - Pipeline by Pfizer Inc., H2 2015
Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H2 2015
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H2 2015
Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2015
Diabetic Nephropathy - Pipeline by Shire Plc, H2 2015
Diabetic Nephropathy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Diabetic Nephropathy - Pipeline by Tobira Therapeutics, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H2 2015
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2015
Diabetic Nephropathy - Pipeline by XOMA Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Diabetic Nephropathy Therapeutics - Recent Pipeline Updates, H2 2015
Diabetic Nephropathy - Dormant Projects, H2 2015
Diabetic Nephropathy - Dormant Projects (Contd..1), H2 2015
Diabetic Nephropathy - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Diabetic Nephropathy, H2 2015
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report